Adeno-associated Viral Vector
Adeno-associated Viral Vector - Related Videos
08:47
Intracranial Injection of Adeno-associated Viral Vectors
0 Views •
Cited by 56 •
2010
Here we present the intracranial injection of AAV vectors for fluorescent labeling of neurons and glia in the visual cortex.
08:35
Production and Titering of Recombinant Adeno-associated Viral Vectors
0 Views •
Cited by 149 •
2011
Recombinant adeno-associated virus (rAAVs) vectors are becoming increasingly valuable for in vivo studies in animals. We describe how rAAVs can be produced in the laboratory and how these vectors can be titered to give an accurate reading of the number of infectious particles produced.
08:33
Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
0 Views •
Cited by 12 •
2016
This manuscript describes how viral vector-mediated local gene delivery provides an attractive way to express transgenes in the central nervous system. The protocol outlines all crucial steps to perform a viral vector injection in the substantia nigra of the rat to develop a viral vector-based animal model for Parkinson's disease.
03:35
Affinity Chromatography-Based Purification of Adeno-Associated Virus Vectors
0 Views •
2026
Source: Rghei, A. D., et al. Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models. J. Vis. Exp. (2021)The video demonstrates purification of recombinant adeno-associated virus (AAV) vectors from crude host lysate using a heparin-based affinity matrix. Viral particles bind to immobilized heparin, while impurities are washed away. A high-salt buffer releases intact viruses, which is collected in enriched fractions. These fractions are...
02:08
Transduction of a Humanized Rat Liver Using Adeno-associated Virus Vectors
0 Views •
2026
Source: Hiller, T., et al. Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2. J. Vis. Exp., (2016)This video demonstrates adeno-associated virus-mediated gene delivery in a humanized rat liver scaffold. The vector delivers a transgene encoding a fluorescent reporter and gene-silencing RNA into liver cells via receptor-mediated endocytosis. This model supports efficient transduction in a perfused 3D liver tissue system.
FAQs
Capsid selection is a major determinant of where an AAV vector travels and which cells it can enter. Different capsids can produce different patterns of tissue distribution and cell-type specificity, so researchers choose among them according to the target brain region and neuronal population. This choice directly affects how selectively a genetic payload is delivered.
Promoter choice controls where the delivered genetic material is expressed after the vector enters a cell. Pairing a promoter with the intended target can help concentrate fluorescent, engineered, or therapeutic protein production in selected cells. Because expression characteristics also influence experimental outcomes, promoter selection is considered alongside capsid, injection site, and dose.
Once released inside a target cell, the Adeno-associated Viral Vector’s DNA may persist as episomal genetic material or support expression from a selected promoter. This distinction helps explain why delivery can provide sustained genetic activity without producing infectious virus, an important property for neural experiments.
An effective brain delivery plan must coordinate injection site and dose. The injection site determines which region receives the vector, while dose contributes to the extent of tissue distribution and expression. Adjusting these variables allows researchers to match delivery to a circuit, cell population, or therapeutic target, although each choice can change the resulting pattern.
Planning an AAV experiment begins by matching the biological goal to four linked choices: capsid, injection site, promoter, and dose. Researchers then use the vector to deliver a selected genetic material and assess the resulting distribution or expression in the targeted neural tissue. This coordinated design is more informative than treating any single parameter as sufficient.
In neuroscience, AAV vectors support several experimental goals: labeling neuronal circuits, expressing fluorescent proteins, producing engineered proteins, manipulating cell activity, and delivering therapeutic genes to brain regions. These applications let investigators connect genetic delivery with circuit organization, neuronal function, or disease-focused intervention. The same platform therefore serves both basic studies and neurological disorder research.